Literature DB >> 17976102

Electrocardiographic patterns during: pacing the great cardiac and middle cardiac veins.

Michael C Giudici1, Darryn W Tigrett, Jacqueline I Carlson, Terri D Lorenz, Deborah L Paul, S Serge Barold.   

Abstract

BACKGROUND: The electrocardiogram (ECG) patterns during pacing from the great cardiac vein (GCV) and the middle cardiac vein (MCV) are not well known.
METHODS: We recorded 12-lead ECGs during GCV and MCV pacing in 26 patients undergoing implantation of a cardiac resynchronization device. The left ventricular (LV) lead was passed down the GCV (n = 19) or MCV (n = 7) prior to moving it to a lateral or posterolateral vein for permanent implantation. RESULTS AND
CONCLUSIONS: Pacing within the GCV resulted in a left bundle branch block (LBBB) morphology with no or minimal R-wave in V(1) in 14 patients and a right bundle branch block (RBBB) pattern (R > S in lead V(1)) in four patients. In one patient, lead V1 during GCV pacing was isoelectric (R = S). A more distal pacing site in the GCV yielded a LBBB pattern in all the patients. All leads placed in the MCV resulted in a LBBB configuration. An ECG pattern with a RBBB pattern was invariably recorded during LV pacing in 125 consecutive outpatients with biventricular pacemakers and LV leads in the posterolatral and lateral coronary veins. Knowledge of the ECG patterns from various pacing sites in the coronary venous system may be helpful for troubleshooting all types of pacing systems, especially those where the coronary venous pacing site is unintentional.

Entities:  

Mesh:

Year:  2007        PMID: 17976102     DOI: 10.1111/j.1540-8159.2007.00874.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  1 in total

1.  The postimplantation electrocardiogram predicts clinical response to cardiac resynchronization therapy.

Authors:  Edward Coverstone; Justin Sheehy; Robert E Kleiger; Timothy W Smith
Journal:  Pacing Clin Electrophysiol       Date:  2015-03-16       Impact factor: 1.976

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.